Nevro Shares Face Mounting Pressure as Fundamentals Worsen

Nevro Corp. is confronting significant operational headwinds that have cast a pall over its stock. Recent financial results and a downward revision of future guidance have substantially weakened investor confidence in the medical technology firm, with market sentiment turning decidedly negative.

Q4 Performance Disappoints, Guidance Lowered

The company’s operational metrics for the final quarter of 2024 revealed underlying weaknesses. Globally, Nevro recorded revenue of $96.9 million, representing a 7% year-over-year decline. A particularly alarming signal was a 15.2% collapse in U.S. test procedures, indicating substantial difficulty in acquiring new customers.

• Q4 2024 Revenue Decline: Fell 7% to $96.9 million
• U.S. Test Procedure Volume: Plummeted 15.2%
• Revised 2024 Outlook: Guidance lowered to a range of $400-$405 million
• Profitability Squeeze: Lower sales volumes are pressuring margins

In response to these challenges, management revised its full-year 2024 revenue projection downward to $400-$405 million. This new forecast implies an annual decrease of 5-6%. Compounding the issue, falling sales volumes are exerting pressure on gross margins, a profitability challenge expected to persist into 2025.

Should investors sell immediately? Or is it worth buying Nevro?

Analyst Sentiment Reflects Deep-Seated Caution

The prevailing analyst consensus for Nevro shares is a “Hold” rating. A breakdown of recommendations from 24 market experts shows a cautious stance: 46% advise holding, while only 21% suggest buying and 17% advocate strong buying. The bearish contingent, comprising 13% sell and 4% strong sell recommendations, though smaller, underscores the divided and prudent outlook among professionals.

This wariness is quantified by Nevro’s Fear & Greed Index reading of 39, which signals a market dominated by “Fear.” This level of risk aversion among investors suggests the potential for continued downward pressure on the share price.

Price Targets Suggest Limited Upside Potential

Current price projections reinforce the negative trend. The consensus forecast for September 2025 places Nevro’s stock at approximately $5.82. The anticipated trading range is exceptionally narrow, from $5.80 to $5.84, indicating a pronounced lack of positive momentum. Looking further out to October 2025, analysts project a marginal further decline of 0.04%, with the price expected to reach $5.84 per share. These forecasts raise serious questions about the stock’s ability to initiate a meaningful recovery in the near term.